Loading
A phase 3 trial of Talimogene laherparepvec in Melanoma, run by BioVex Limited, completed.
An Extended Use Study of Safety and Efficacy of Talimogene Laherparepvec in Melanoma is a phase 3 interventional study registered as NCT01368276 by BioVex Limited, with 31 participants recorded, started 2010-10 and reaching its primary completion in 2014-09. Interventions recorded: Talimogene Laherparepvec, Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF). Conditions recorded: Melanoma.
Linked to the drug Talimogene laherparepvec because the registry names it among its interventions and Melanoma among its conditions. Registry record only: no result has been read by an editor.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
31 enrolled.
95% CI NA to NA; Figures from the ClinicalTrials.gov results section (first posted 2015-12-18), not from a publication · 95% CI 38.8 to 75.5
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Objective Response Rate | GM-CSF | 3 | 100% | - | 0.2645 | link |
| Talimogene Laherparepvec | 28 | 57.1% |
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Talimogene laherparepvec, Amgen, Melanoma and the tag pipeline.
Shares Talimogene laherparepvec, Amgen, Melanoma and the tag pipeline.
Shares Amgen and the tag pipeline.
Shares Amgen and the tag pipeline.
Shares Amgen and the tag pipeline.
Shares Amgen and the tag pipeline.
Shares Amgen and the tag pipeline.
Shares Melanoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/